ATE526030T1 - Protein s zur verwendung als neuroprotektives mittel - Google Patents

Protein s zur verwendung als neuroprotektives mittel

Info

Publication number
ATE526030T1
ATE526030T1 AT03799306T AT03799306T ATE526030T1 AT E526030 T1 ATE526030 T1 AT E526030T1 AT 03799306 T AT03799306 T AT 03799306T AT 03799306 T AT03799306 T AT 03799306T AT E526030 T1 ATE526030 T1 AT E526030T1
Authority
AT
Austria
Prior art keywords
protein
stroke
activities
agents
oxygenation
Prior art date
Application number
AT03799306T
Other languages
English (en)
Inventor
Berislav Zlokovic
John Griffin
Original Assignee
Zz Biotech L L C
Univ Rochester
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zz Biotech L L C, Univ Rochester, Scripps Research Inst filed Critical Zz Biotech L L C
Application granted granted Critical
Publication of ATE526030T1 publication Critical patent/ATE526030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT03799306T 2002-09-30 2003-09-30 Protein s zur verwendung als neuroprotektives mittel ATE526030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41433302P 2002-09-30 2002-09-30
PCT/US2003/030638 WO2004030619A2 (en) 2002-09-30 2003-09-30 Protein s protects the nervous system from injury

Publications (1)

Publication Number Publication Date
ATE526030T1 true ATE526030T1 (de) 2011-10-15

Family

ID=32069725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03799306T ATE526030T1 (de) 2002-09-30 2003-09-30 Protein s zur verwendung als neuroprotektives mittel

Country Status (6)

Country Link
US (1) US7968515B2 (de)
EP (1) EP1572134B1 (de)
AT (1) ATE526030T1 (de)
AU (1) AU2003277034A1 (de)
CA (1) CA2499458C (de)
WO (1) WO2004030619A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030619A2 (en) 2002-09-30 2004-04-15 Socratech L.L.C. Protein s protects the nervous system from injury
WO2007018400A1 (en) * 2005-08-11 2007-02-15 Medigenes Co., Ltd Pharmaceutical composition for the treatment of nerve damage comprising blood plasma or serum
CN104122396A (zh) * 2013-04-23 2014-10-29 中国科学院上海生命科学研究院 维生素k依赖性蛋白s作为糖尿病标志物的应用
DE102013209820A1 (de) 2013-05-27 2014-11-27 Hamm Ag Selbstfahrende Straßenbaumaschine, insbesondere Straßenwalze, sowie Verfahren zum Fahren und Lenken einer Straßenbaumaschine
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
US5321123A (en) 1991-07-02 1994-06-14 The Scripps Research Institute Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
US5405946A (en) 1992-12-02 1995-04-11 The Scripps Research Institute Recombinant protein S variants deficient in C4BP binding activity, compositions and therapeutic methods
AU6985594A (en) 1993-06-30 1995-01-24 Bonno Nammen Bouma Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods
DE4418635C2 (de) 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
AU2001238034A1 (en) 2000-02-04 2001-08-14 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US20030165485A1 (en) * 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
WO2004030619A2 (en) 2002-09-30 2004-04-15 Socratech L.L.C. Protein s protects the nervous system from injury
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity

Also Published As

Publication number Publication date
CA2499458C (en) 2013-11-12
AU2003277034A8 (en) 2004-04-23
US7968515B2 (en) 2011-06-28
EP1572134B1 (de) 2011-09-28
EP1572134A4 (de) 2008-07-09
WO2004030619A8 (en) 2004-11-25
WO2004030619A3 (en) 2005-06-02
EP1572134A2 (de) 2005-09-14
US20060052281A1 (en) 2006-03-09
WO2004030619A2 (en) 2004-04-15
CA2499458A1 (en) 2004-04-15
AU2003277034A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
DE60335244D1 (de) Behandlung von verletzungen des zentralen nervensystems
ATE398459T1 (de) Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
WO2000027422A3 (en) Methods and compositions for treating or preventing peripheral neuropathies
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
DE69943287D1 (de) Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen
WO2002036829A3 (en) Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69433309D1 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
DE69633336D1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
ATE504310T1 (de) Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
ATE526030T1 (de) Protein s zur verwendung als neuroprotektives mittel
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
EP1186672A3 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
DE59710517D1 (de) Adamantanaminenderivate zur bekämpfung von viren der familie bornaviridae
WO2003039487A3 (en) Cyclo(prolyl-glycine) and methods of use to treat neural disorders
DE602004021933D1 (de) 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3-carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen
CA2534303A1 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties